Pulse Biosciences reaches enrollment target in AF study
Pulse Biosciences said it achieved the enrollment target in its NANOPULSE-AF IDE pivotal clinical study evaluating the nPulse cardiac catheter system for atrial fibrillation treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pulse Biosciences NANOPULSE-AF Study reaches enrollment target
Pulse Biosciences announced its NANOPULSE-AF Study evaluating the nPulse™ Cardiac Catheter System has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study achieved enrollment three months ahead of its original nine-month timeline.
Pulse Biosciences Reaches Enrollment Target in Atrial Fibrillation Study
Pulse Biosciences announced its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study is evaluating the nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation using the company's nano-PFA technology.